AdvantaMeds Solutions USA Fund 1, Inc., a cannabis corporation, announces that the US SEC approved its Convertible Preferred Stock Shares for sale. The company appears to be the first ever Convertible Preferred Stock Shares approved for a cannabis operation.
With US SEC approval, the company, its legal team and corporate advisors remain focused on funding the Convertible Preferred Stock Shares through a number of underwriters.
Convertible Preferred Stock Shares proceeds enable AdvantaMeds to grow operations with the construction of potentially the largest fully licensed and approved commercial cannabis facility in North America. AdvantaMeds has entered into a purchase agreement with a company in Colorado that owns a 104,000 sq. ft. industrial building. Investment proceeds will be used for improvements to increase the size to a 223,270 sq. ft. facility.
The increasing demand for cannabis as a medicine for a number of aliments continues to be a proven alternative to pharmaceutical regiments. Positioning the corporation to take maximum advantage of this demand with high-quality products remains a major operational objective.
Management believes that it can obtain increasing revenues, garner greater market share and look for and close upon quality acquisitions to increase its presence as a commercial cannabis operator.
Geoff Thompson, President, AdvantaMeds Solutions USA Fund 1, Inc., states, “After months of hard work we finally received AdvantaMeds’ US SEC Convertible Preferred Stock Shares approval. As an historical event, not just for Advantameds, but for the whole cannabis industry, regulators allowed a Convertible Preferred Stock Shares issuance for an industry that in the past wasn’t taken seriously.”
He further states, “Convertible Preferred Stock Shares holders who purchase a stake in Advantameds, become the first in this historic event for both the corporation and the cannabis industry.”
Adavantameds Solutions USA Fund 1, Inc. continues with commitments in earnest to provide a high-quality, legally regulated cannabis product which can provide medical relief to the inflicted, but also provide a positive balance sheet and bottom-line earnings for its investors.